Cover Image

Cerebral amyloid angiopathy in streptozotocin rat model of sporadic Alzheimer’s disease: a long-term follow up study

Cerebral amyloid angiopathy is manifested as accumulation of amyloid β (Aβ) peptide in the wall of meningeal and cerebral arteries, arterioles and capillaries and is frequently found postmortem in sporadic Alzheimer’s disease (sAD) patients. It is difficult to assess when and how cerebral amyloid an...

Full description

Saved in:
Bibliographic Details
Main Authors: Salkovic-Petrisic, Melita (Author) , Osmanovic-Barilar, Jelena (Author) , Brückner, Martina K. (Author) , Hoyer, Siegfried (Author) , Arendt, Thomas (Author) , Riederer, Peter (Author)
Format: Article (Journal)
Language:English
Published: 30 April 2011
In: Journal of neural transmission
Year: 2011, Volume: 118, Issue: 5, Pages: 765-772
ISSN:1435-1463
DOI:10.1007/s00702-011-0651-4
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1007/s00702-011-0651-4
Get full text
Author Notes:Melita Salkovic-Petrisic, Jelena Osmanovic-Barilar, Martina K. Brückner, Siegfried Hoyer, Thomas Arendt, Peter Riederer
Description
Summary:Cerebral amyloid angiopathy is manifested as accumulation of amyloid β (Aβ) peptide in the wall of meningeal and cerebral arteries, arterioles and capillaries and is frequently found postmortem in sporadic Alzheimer’s disease (sAD) patients. It is difficult to assess when and how cerebral amyloid angiopathy develops and progresses in humans in vivo, which is why animal AD models are used. Streptozotocin-intracerebroventricularly (STZ-icv) treated rats have been recently proposed as the model of sAD which develops insulin resistant brain state preceding Aβ pathology development. Vascular Aβ deposits in the brain of STZ-icv-treated rats (3 months old at the time of icv treatment) were visualized by Thioflavine-S staining, Congo red staining and Aβ immunohistochemistry. Thioflavine-S and Congo red staining revealed diffuse congophilic deposits in the wall of meningeal and cortical blood vessels both 6 and 9 months after the STZ-icv treatment. Preliminary Aβ1-42 and Aβ1-16 immunohistochemistry experiments showed positive staining in blood vessels 3 and 9 months after the STZ-icv treatment, respectively. Results suggest that cerebral amyloid angiopathy observed 6 and 9 months after the STZ-icv treatment seems to be a continuation and progression of the amyloid pathology observed already 3 months following the STZ-icv treatment in this non-transgenic sAD animal model.
Item Description:Gesehen am 04.10.2022
Physical Description:Online Resource
ISSN:1435-1463
DOI:10.1007/s00702-011-0651-4

Similar Items